A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Clinical trial NCT04094610 · RECRUITING

Trial details

NCT number: NCT04094610
Sponsor: Turning Point Therapeutics, Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Locally Advanced Solid Tumors Metastatic Solid Tumors Lymphoma Primary CNS Tumors

Start date: 2020-03-12
Primary completion: 2026-09-30
Enrollment: 75

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.